Cedax is a drug owned by Si Pharmaceuticals Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 30, 2013. Details of Cedax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5599557 | Stable hydrated cephalosporin dry powder for oral suspension formulation |
Apr, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Cedax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cedax's family patents as well as insights into ongoing legal events on those patents.
Cedax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cedax's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 30, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cedax Generics:
There are no approved generic versions for Cedax as of now.
Alternative Brands for Cedax
Cedax which is used for treating respiratory infections caused by susceptible microorganisms in adults aged 18 and older., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Sanofi Aventis Us |
| |||
About Cedax
Cedax is a drug owned by Si Pharmaceuticals Llc. It is used for treating respiratory infections caused by susceptible microorganisms in adults aged 18 and older. Cedax uses Ceftibuten Dihydrate as an active ingredient. Cedax was launched by Si Pharms in 1995.
Approval Date:
Cedax was approved by FDA for market use on 20 December, 1995.
Active Ingredient:
Cedax uses Ceftibuten Dihydrate as the active ingredient. Check out other Drugs and Companies using Ceftibuten Dihydrate ingredient
Treatment:
Cedax is used for treating respiratory infections caused by susceptible microorganisms in adults aged 18 and older.
Dosage:
Cedax is available in the following dosage forms - for suspension form for oral use, capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 180MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | FOR SUSPENSION | Discontinued | ORAL |
| EQ 90MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | FOR SUSPENSION | Discontinued | ORAL |
| EQ 400MG BASE | CAPSULE | Discontinued | ORAL |